The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 12, 2015
Filed:
Mar. 10, 2011
Jaume Pons, San Bruno, CA (US);
Jeffrey Raymond Chabot, Medford, MA (US);
Javier Fernando Chaparro Riggers, San Mateo, CA (US);
Bruce Charles Gomes, Ashburnham, MA (US);
Hong Liang, San Francisco, CA (US);
Kapil Mayawala, Peabody, MA (US);
Jerome Thomas Mettetal, Ii, Cambridge, MA (US);
Arvind Rajpal, San Francisco, CA (US);
David Louis Shelton, Oakland, CA (US);
Jaume Pons, San Bruno, CA (US);
Jeffrey Raymond Chabot, Medford, MA (US);
Javier Fernando Chaparro Riggers, San Mateo, CA (US);
Bruce Charles Gomes, Ashburnham, MA (US);
Hong Liang, San Francisco, CA (US);
Kapil Mayawala, Peabody, MA (US);
Jerome Thomas Mettetal, II, Cambridge, MA (US);
Arvind Rajpal, San Francisco, CA (US);
David Louis Shelton, Oakland, CA (US);
Rinat Neuroscience Corp., South San Francisco, CA (US);
Pfizer Inc., New York, NY (US);
Abstract
The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH (i.e., pH 6.0 or 5.5). In other words, the Kor kratio at pH 5.5/pH 7.4 or at pH 6.0/pH 7.4 is more than, or ranges between, 2, 3, 4, 8, 10, 16, 20, 30, 40, or 100 or more. Such pH dependent antibodies preferentially dissociate from the antigen in the endosome. This can increase antibody half life, as compared to antibodies with equivalent Ks at pH 7.4 but with no pH dependent binding, when the antigen is one that undergoes antigen-mediated clearance (e.g., PCSK9). Antibodies with pH dependent binding can decrease total antigen half life when the antigen undergoes reduced clearance when bound to antibody (e.g., IL6). Antibodies with pH dependent binding can also prolong the decrease in antigen which is not antibody-bound. This can be important when antagonizing a target antigen typically present at high levels (e.g., IgE, DKK1, C5 and SOST). In addition, such antibodies can increase antigen half life when the antigen is a receptor and the receptor has increased clearance when bound to antibody (e.g., GMCSF receptor).